UCLA Researchers Develop Personalized Vaccine for Aggressive Brain Cancer, Showing Promising Long-Term Survival
Researchers at UCLA Health, led by neurosurgeon Linda Liau, MD, PhD, and tumor immunologist Robert Prins, PhD, have developed a personalized vaccine for glioblastoma, the most aggressive form of brain cancer. This therapeutic vaccine, known as DCVax-L, utilizes a patient's own immune system to target and attack brain tumors. The process involves collecting tumor tissue during surgery and isolating dendritic cells from the patient's blood. These dendritic cells are then exposed to proteins from the patient's tumor in a laboratory setting, effectively training them to recognize and combat the cancer. Once injected back into the patient, these trained cells activate an immune response specifically directed against the tumor. Unlike traditional preventative vaccines, this approach is designed to help the immune system fight existing cancer. Approximately two dozen patients who received this vaccine through clinical trials have achieved long-term survival, a significant outcome for a disease where survival beyo...